BMRN · XBRL financial data

BioMarin Pharmaceutical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BMRN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	646*	649	712	746	747*	745	825	776	875*	766	990	1,025
Cost of revenue	135*	125	130	188	136*	152	150	140	276*	195	203	205
Research and development	206*	205	184	185	174*	159	161	409	192*	179	207	—
Selling, general and administrative	275*	226	263	253	267*	206	232	268	446*	258	396	334
Other operating income (expense)	(7)*	1	(5)	5	(7)*	(2)	5	5	1*	4	3	1
Operating income (loss)	14*	88	120	114	161*	224	277	(47)	(45)*	130	111	(82)
Interest income	18*	19	20	18	18*	19	19	18	19*	23	10	5
Interest expense	6*	4	4	3	3*	2	2	2	3*	10	61	55
Income tax expense (benefit)	(1)*	17	25	28	45*	52	57	4	19*	36	17	(9)
Net income (loss)	20*	89	107	106	125*	186	241	(31)	(47)*	106	45	(123)
Earnings per share, basic USD per share	0.11*	0.47	0.56	0.56	0.66*	0.97	1.25	(0.16)	(0.24)*	0.55	0.23	(0.63)
Earnings per share, diluted USD per share	0.11*	0.46	0.55	0.55	0.66*	0.95	1.23	(0.16)	(0.23)*	0.54	0.23	(0.63)
Weighted average shares, basic millions of shares	188*	189	190	190	191*	191	192	192	192*	192	193	194
Weighted average shares, diluted millions of shares	186*	199	201	197	190*	196	197	192	204*	198	194	194

Balance sheet

CSV

Fiscal quarters (BMRN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	755	747	972	675	943	1,049	1,214	1,250	1,312	2,222	874	736
Marketable securities	319	300	252	255	195	224	218	228	249	0	0	0
Marketable securities, non-current	611	621	557	562	521	507	509	513	492	0	0	0
Accounts receivable	634	637	691	778	661	739	856	790	908	904	1,061	1,076
Inventory	1,107	1,138	1,184	1,179	1,233	1,275	1,340	1,382	1,299	1,273	1,783	1,796
Total current assets	2,956	2,985	3,260	3,057	3,232	3,468	3,805	3,855	3,953	4,605	3,972	3,921
Property and equipment, net	1,066	1,060	1,053	1,045	1,043	1,033	1,030	1,038	953	958	990	980
Right-of-use asset	43	—	—	—	29	—	—	—	35	—	—	—
Goodwill	196	196	196	196	196	196	196	196	196	196	656	666
Total assets	6,842	6,873	7,067	6,851	6,989	7,147	7,456	7,615	7,594	8,591	11,723	11,569
Accounts payable	—	—	—	—	—	—	—	—	31	—	—	131
Current portion of long-term debt	—	—	—	—	—	—	—	—	0	—	658	659
Total current liabilities	1,177	1,088	1,067	716	607	628	684	798	759	793	1,664	1,605
Long-term debt	—	—	—	—	—	—	—	—	597	—	3,528	3,515
Lease liability, non-current	38	—	—	—	31	—	—	—	37	—	—	—
Total liabilities	1,890	1,799	1,781	1,438	1,331	1,354	1,429	1,558	1,507	2,379	5,402	5,313
Retained earnings (accumulated deficit)	(622)	(533)	(426)	(320)	(195)	(9)	232	201	154	260	304	182
Total stockholders' equity	4,952	5,074	5,286	5,413	5,658	5,793	6,027	6,057	6,087	6,212	6,322	6,256
Total liabilities and equity	6,842	6,873	7,067	6,851	6,989	7,147	7,456	7,615	7,594	8,591	11,723	11,569
Common shares outstanding (cover page) millions of shares	189	190	190	191	191	192	192	192	192	193	194	194

Cash flows

CSV

Fiscal quarters (BMRN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	20*	89	107	106	125*	186	241	(31)	(47)*	106	45	(123)
Stock-based compensation	55*	58	48*	43*	52*	38	48*	49*	47*	43	76*	54*
Depreciation and amortization	27*	27	26*	19*	24*	22	19*	18*	20*	16	98*	130*
Net cash from operating activities	27*	47	119*	221*	186*	174	185*	369*	100*	221	168*	188*
Purchases of property and equipment	29*	26	21*	18*	20*	17	17*	28*	41*	21	29*	28*
Net cash from investing activities	(65)*	(14)	90*	(16)*	76*	(28)	(13)*	(331)*	(42)*	726	(5,102)*	(307)*
Net cash from financing activities	11*	(43)	13*	(499)*	3*	(39)	(5)*	(2)*	3*	813	2,738*	(19)*
Net change in cash	(30)*	(8)	225*	(297)*	267*	106	165*	36*	62*	1,761	(2,198)*	(138)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Biomarin Pharmaceutical	874	990	168*	193.6M	—	Q2 FY26 10-QJun 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.